Trials / Completed
CompletedNCT01288235
Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation
A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine Adn Ototoxicity Outcomes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 1 Year – 25 Years
- Healthy volunteers
- Not accepted
Summary
Some patients with brain tumors receive standard radiation to help prevent tumor growth. Although standard radiation kills tumor cells, it can also damage normal tissue in the process and lead to more side effects. This research study is looking at a different form of radiation called proton radiotherapy which helps spare normal tissues while delivering radiation to the tumor or tumor bed. Proton techniques irradiate 2-3 times less normal tissue then standard radiation. This therapy has been used in treatment of other cancers and information from those other research studies suggests that this therapy may help better target brain tumors then standard radiation.
Detailed description
\- Participants will receive proton radiotherapy at the Francis H. Burr Proton Therapy Center which is located at the Massachusetts General Hospital. They will receive the proton radiotherapy 5 days per week. The number of weeks the participant will be receiving proton radiotherapy depends upon the tumor type and location and how well they are tolerating the treatment. Participant's will have a physical exam weekly during proton radiotherapy treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Proton radiotherapy | 5 days a week |
Timeline
- Start date
- 2011-02-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2011-02-02
- Last updated
- 2025-06-03
- Results posted
- 2025-06-03
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01288235. Inclusion in this directory is not an endorsement.